175 related articles for article (PubMed ID: 10912937)
1. Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markers.
Porcell AI; De Young BR; Proca DM; Frankel WL
Mod Pathol; 2000 Jul; 13(7):773-8. PubMed ID: 10912937
[TBL] [Abstract][Full Text] [Related]
2. Differential diagnosis of malignant epithelial tumours in the liver: an immunohistochemical study on liver biopsy material.
Al-Muhannadi N; Ansari N; Brahmi U; Satir AA
Ann Hepatol; 2011; 10(4):508-15. PubMed ID: 21911893
[TBL] [Abstract][Full Text] [Related]
3. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma.
Lau SK; Prakash S; Geller SA; Alsabeh R
Hum Pathol; 2002 Dec; 33(12):1175-81. PubMed ID: 12514785
[TBL] [Abstract][Full Text] [Related]
4. A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver.
Morrison C; Marsh W; Frankel WL
Mod Pathol; 2002 Dec; 15(12):1279-87. PubMed ID: 12481008
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1.
Radwan NA; Ahmed NS
Diagn Pathol; 2012 Oct; 7():149. PubMed ID: 23111165
[TBL] [Abstract][Full Text] [Related]
6. MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers.
Proca DM; Niemann TH; Porcell AI; DeYoung BR
Appl Immunohistochem Mol Morphol; 2000 Jun; 8(2):120-5. PubMed ID: 10937059
[TBL] [Abstract][Full Text] [Related]
7. Comparative immunohistochemical study of primary and metastatic carcinomas of the liver.
Ma CK; Zarbo RJ; Frierson HF; Lee MW
Am J Clin Pathol; 1993 May; 99(5):551-7. PubMed ID: 7684185
[TBL] [Abstract][Full Text] [Related]
8. Histologic differentiation of hepatocellular carcinoma from adenocarcinoma by a simple panel: evaluation of the pitfalls.
Geramizadeh B; Boub R; Rahsaz M
Indian J Pathol Microbiol; 2007 Jul; 50(3):507-10. PubMed ID: 17883119
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of immunohistochemical markers for differential diagnosis of hepatocelluar carcinoma and cholangiocarcinoma.
Ryu HS; Lee K; Shin E; Kim SH; Jing J; Jung HY; Lee H; Jang JJ
Tumori; 2012; 98(4):478-84. PubMed ID: 23052165
[TBL] [Abstract][Full Text] [Related]
10. The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma.
Shiran MS; Isa MR; Sherina MS; Rampal L; Hairuszah I; Sabariah AR
Malays J Pathol; 2006 Dec; 28(2):87-92. PubMed ID: 18376797
[TBL] [Abstract][Full Text] [Related]
11. Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma.
Itoyama M; Hata M; Yamanegi K; Yamada N; Ohyama H; Hirano H; Terada N; Nakasho K
Med Mol Morphol; 2012 Dec; 45(1):7-13. PubMed ID: 22431178
[TBL] [Abstract][Full Text] [Related]
12. [Anatomo-pathologic diagnostic interpretation of nodular hepatic lesions].
Chiaramondia M; Ceppa P; Baccini P; Badini A; Castellaneta A
Pathologica; 1993; 85(1100):687-99. PubMed ID: 8170717
[TBL] [Abstract][Full Text] [Related]
13. An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19.
Tsuji M; Kashihara T; Terada N; Mori H
Pathol Int; 1999 Apr; 49(4):310-7. PubMed ID: 10365850
[TBL] [Abstract][Full Text] [Related]
14. Combined hepatocellular-cholangiocarcinoma with stem cell features, ductal plate malformation subtype: a case report and proposal of a new subtype.
Terada T
Int J Clin Exp Pathol; 2013; 6(4):737-48. PubMed ID: 23573322
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas.
Stroescu C; Herlea V; Dragnea A; Popescu I
J Gastrointestin Liver Dis; 2006 Mar; 15(1):9-14. PubMed ID: 16680226
[TBL] [Abstract][Full Text] [Related]
16. S-100-positive nerve fibers in hepatocellular carcinoma and intrahepatic cholangiocarcinoma: an immunohistochemical study.
Terada T; Matsunaga Y
Pathol Int; 2001 Feb; 51(2):89-93. PubMed ID: 11169146
[TBL] [Abstract][Full Text] [Related]
17. cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma.
Xiao SY; Wang HL; Hart J; Fleming D; Beard MR
Am J Pathol; 2001 Oct; 159(4):1415-21. PubMed ID: 11583969
[TBL] [Abstract][Full Text] [Related]
18. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
Shirakawa H; Kuronuma T; Nishimura Y; Hasebe T; Nakano M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Int J Oncol; 2009 Mar; 34(3):649-56. PubMed ID: 19212669
[TBL] [Abstract][Full Text] [Related]
19. Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma.
Röcken C; Licht J; Roessner A; Carl-McGrath S
J Clin Pathol; 2005 Oct; 58(10):1069-75. PubMed ID: 16189153
[TBL] [Abstract][Full Text] [Related]
20. HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates.
Wang L; Vuolo M; Suhrland MJ; Schlesinger K
Acta Cytol; 2006; 50(3):257-62. PubMed ID: 16780018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
